文献速递乳腺癌

靶向PI3K/AKT/mTOR通路治疗间质型三阴性乳腺癌:mTOR抑制联合脂质体多柔比星与贝伐珠单抗的1期试验证据

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
PubMed 文献 · JAMA Oncol · 2017-01-01

该1期研究在晚期化生性三阴性乳腺癌患者中评估mTOR抑制剂联合脂质体多柔比星和贝伐珠单抗的安全性与疗效,52例患者中客观缓解率为21%,临床获益率为40%,PI3K通路异常与客观缓解率改善显著相关(31% vs 0%;P=0.04)。

要点

  • mTOR抑制联合脂质体多柔比星和贝伐珠单抗在化生性三阴性乳腺癌中显示活性,客观缓解率21%,临床获益率40%。
  • PI3K通路异常患者客观缓解率显著改善(31% vs 0%;P=0.04),但临床获益率无显著差异(44% vs 45%;P>0.99)。

核心结论

  • 以化生性三阴性乳腺癌作为间质型三阴性乳腺癌的替代,DAT和DAE方案具有显著活性,客观缓解仅限于PI3K通路异常患者,建议开展随机试验测试DAT和DAE用于化生性及非化生性间质型三阴性乳腺癌,尤其在检出PI3K通路异常时。

研究设计与样本

  • 在德克萨斯大学MD安德森癌症中心开展的1期剂量递增和剂量扩展研究,纳入晚期化生性三阴性乳腺癌患者,2009年4月16日至2014年11月4日入组,数据截止2015年11月1日。

主要发现

  • 52例女性患者(中位年龄58岁,范围37-79岁)接受DAT(N=39)或DAE(N=13)治疗,客观缓解率为21%(完全缓解4例[8%];部分缓解7例[13%]),10例(19%)患者疾病稳定至少6个月,临床获益率为40%。
  • 43例患者有组织可检测,其中32例(74%)存在PI3K通路异常。
  • PI3K通路异常与客观缓解率显著改善相关(31% vs 0%;P=0.04),但临床获益率无显著差异(44% vs 45%;P>0.99)。

关键数值与推荐

  • 客观缓解率21%(完全缓解4例[8%];部分缓解7例[13%]),临床获益率40%。
  • PI3K通路异常患者客观缓解率31% vs 无异常患者0%(P=0.04),临床获益率44% vs 45%(P>0.99)。

临床怎么用

  • 作者建议开展随机试验测试DAT和DAE用于化生性三阴性乳腺癌以及非化生性间质型三阴性乳腺癌,尤其在检出PI3K通路异常时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy. While assays to identify mesenchymal TNBC are under development, metaplastic breast cancer serves as a clinically identifiable surrogate to evaluate potential regimens for mesenchymal TNBC. OBJECTIVE: To assess safety and efficacy of mammalian target of rapamycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with advanced metaplastic TNBC. DESIGN, SETTING, AND PARTICIPANTS: Phase 1 study with dose escalation and dose expansion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC. Patients were enrolled from April 16, 2009, to November 4, 2014, and followed for outcomes with a cutoff date of November 1, 2015, for data analysis. INTERVENTIONS: Liposomal doxorubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles. MAIN OUTCOMES AND MEASURES: Safety and response. When available, archived tissue was evaluated for aberrations in the PI3K pathway. RESULTS: Fifty-two women with metaplastic TNBC (median age, 58 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE) (N = 13). The objective response rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical benefit rate of 40%. Tissue was available for testing in 43 patients, and 32 (74%) had a PI3K pathway aberration. Presence of PI3K pathway aberration was associated with a significant improvement in objective response rate (31% vs 0%; P = .04) but not clinical benefit rate (44% vs 45%; P > .99). CONCLUSIONS AND RELEVANCE: Using metaplastic TNBC as a surrogate for mesenchymal TNBC, DAT and DAE had notable activity in mesenchymal TNBC. Objective response was limited to patients with PI3K pathway aberration. A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Basho RK, Gilcrease M, Murthy RK, et al. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017. PMID: 27893038. doi:10.1001/jamaoncol.2016.5281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。